| Literature DB >> 30527777 |
Ce Zhang1, Lin Jiang1, Lianjun Xu1, Jian Tian1, Junhao Liu1, Xueyan Zhao1, Xinxing Feng1, Dong Wang1, Yin Zhang1, Kai Sun1, Bo Xu1, Wei Zhao1, Rutai Hui1, Runlin Gao1, Lei Song2, Jinqing Yuan3.
Abstract
Hyperuricemia has been associated with mortality in patients with coronary artery disease (CAD). However, its prognostic value remains unknown in the context of severe CAD with heavy atherosclerotic burden in all 3 vessels. We used data from a large cohort of consecutive patients with severe CAD. The primary end point was all-cause death. Propensity score matching was used to identify 2 cohorts of patients with similar baseline characteristics. A total of 8,529 patients with available serum uric acid data were included in the study. Hyperuricemia was present in 1,207 (14.2%) patients. At baseline, hyperuricemic patients had more co-morbidities, and more often received medical therapy alone. During the median follow-up of 7.5 years, significantly more deaths occurred in hyperuricemic patients compared with normouricemic patients (22.5% vs 13.7%; p < 0.001). Multivariable analyses showed that hyperuricemia was associated with an increased risk of mortality (hazard ratio 1.33; 95% confidence interval 1.15 to 1.53; p < 0.001). Propensity score matching yielded similar results (hazard ratio 1.33; 95% confidence interval 1.11 to 1.61; p = 0.003). The association was relatively consistent across subgroups, except for an interaction between age and hyperuricemia. Addition of uric acid to SYNTAX score II provided significant improvements of reclassification and discrimination for mortality prediction. In conclusion, hyperuricemia is relatively common among patients with severe CAD and is independently associated with mortality. Moreover, uric acid can improve the predictability of a well-established risk score.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30527777 DOI: 10.1016/j.amjcard.2018.11.027
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778